Juan Mu
Overview
Explore the profile of Juan Mu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mu J, Liu M, Wang J, Meng J, Zhang R, Jiang Y, et al.
Adv Clin Exp Med
. 2022 Feb;
31(3):327-335.
PMID: 35148570
Background: A patient with relapsed mantle cell lymphoma (MCL) showed stable disease after receiving ibrutinib therapy as a salvage therapy, after the failure of his first chimeric antigen receptor (CAR)-T...
12.
Miao M, Dai Y, Rui C, Fan Y, Wang X, Fan C, et al.
Diabetol Metab Syndr
. 2021 Dec;
13(1):150.
PMID: 34952629
Background: Gestational diabetes mellitus (GDM) has significant short and long-term health consequences for both the mother and child. There is limited but suggestive evidence that inulin could improve glucose tolerance...
13.
Li X, Liu M, Mou N, Yang Z, Wang J, Mu J, et al.
Oncol Lett
. 2021 Sep;
22(5):788.
PMID: 34584566
The present study aimed to compare the differences between the humanized CD19 chimeric antigen receptor (CAR)-T cell therapy and the murine CD19 CAR-T therapy in recurrent B-acute lymphoblastic leukemia (B-ALL)....
14.
Wu Y, Mu J, Cao J, Li D, Dai Y
Nutr Cancer
. 2021 Jul;
74(5):1519-1526.
PMID: 34323140
Ovarian cancer is one of the most fatal gynecological cancers. For most ovarian cancer patients, nutritional risk or malnutrition may accompany them for life. Regular nutritional risk screening, timely nutritional...
15.
Zhu H, Deng H, Mu J, Lyu C, Jiang Y, Deng Q
Onco Targets Ther
. 2021 Jul;
14:4023-4037.
PMID: 34239307
Background: To observe efficacy of the anti-CD22 chimeric antigen receptor modified (anti-CD22-CAR) T cell salvage therapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and B cell acute lymphoid leukemia...
16.
Liu M, Deng H, Mu J, Li Q, Pu Y, Jiang Y, et al.
Cancer Sci
. 2021 May;
112(7):2642-2651.
PMID: 33932067
The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in...
17.
Cao J, Zhang Y, Mu J, Yang D, Gu X, Zhang J
Hum Cell
. 2021 Apr;
34(4):1185-1196.
PMID: 33813728
Ovarian cancer is a predominant gynecologic malignancy and correlated with high mortality and severe morbidity. Exosomal microRNAs (miRNAs) play crucial roles in various processes during the progression of ovarian cancer,...
18.
Li Q, Mu J, Yuan J, Yang Z, Wang J, Deng Q
Onco Targets Ther
. 2020 Nov;
13:11471-11484.
PMID: 33204102
Purpose: To investigate the donor chimerism changes and curative effects associated with the use of autologous anti-CD19 chimeric antigen receptor (CAR) T cells with B-cell acute lymphoblastic leukemia (B-ALL) presenting...
19.
Liu M, Wang X, Li Z, Zhang R, Mu J, Jiang Y, et al.
Cancer Sci
. 2020 Sep;
111(11):4051-4060.
PMID: 32876369
Ibrutinib might improve the efficacy of anti-CD19 chimeric antigen receptor (CD19 CAR) T-cell therapy in chronic lymphocytic leukemia (CLL). We studied the possibility and mechanism of the synergistic effect of...
20.
Huang A, Wang Y, She X, Mu J, Zhao J
Funct Plant Biol
. 2020 Jun;
42(11):1057-1067.
PMID: 32480745
Hydrogen peroxide is an important intermediate in darkness-induced stomatal closure. In the present work, we provide evidence that copper amine oxidase (CuAO) was involved in H2O2 production in darkness-induced stomatal...